Clinical TrialJun 4, 2026, 04:32 PM
Eledon to Present Updated Trial Results at ADA Scientific Sessions
AI Summary
Eledon Pharmaceuticals announced that updated results from an investigator-initiated trial will be presented at the American Diabetes Association 86th Scientific Sessions. The presentation, titled "Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation," will be delivered by Dr. Piotr Witkowski from the University of Chicago Medicine Transplant Institute on June 7, 2026. This highlights the ongoing development of Eledon's lead product, tegoprubart, an anti-CD40L antibody, for various immune-modulating therapies.
Key Highlights
- Eledon Pharmaceuticals to present updated results from an investigator-initiated trial at the American Diabetes Association 86th Scientific Sessions.
- Presentation titled "Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation."
- The oral presentation will take place on Sunday, June 7, 2026, from 2:30 p.m. to 3:00 p.m. CT.
- The trial is being conducted at the University of Chicago Medicine Transplant Institute by Dr. Piotr Witkowski.
- Eledon's lead investigational product, tegoprubart, is an anti-CD40L antibody.
- The company is conducting studies in kidney allograft, xenotransplantation, islet cell, liver transplantation, and ALS.
Price Impact
More from ELDN